DD
MM
YYYY

PAGES

DD
MM
YYYY

spot_img

PAGES

Home Blog Page 32

Novo Nordisk Turns to OpenAI in High-Stakes Bid to Accelerate Drug Discovery and Regain Weight-Loss Lead

0

In yet another move that underscores how artificial intelligence is rapidly becoming a significant leverage in pharmaceuticals, Novo Nordisk has struck a far-reaching partnership with OpenAI to accelerate drug discovery, streamline clinical development, and sharpen operational efficiency across its global business.

The Danish drugmaker said Tuesday that the alliance is designed to help “bring new and better treatment options to patients faster,” a goal that carries enormous commercial and medical significance as the company battles to reclaim lost ground in the lucrative obesity and diabetes market.

The partnership is seen as a calculated response to intensifying pressure from Eli Lilly and Company, which has steadily eroded Novo’s early lead in the GLP-1 weight-loss segment. What is at stake is not simply innovation prestige, but leadership in a market projected to remain one of the most profitable corners of global healthcare for years.

Novo said the partnership will enable it to use advanced AI systems to analyze highly complex datasets, identify promising therapeutic candidates, and compress the time it takes for a medicine to move from early research to patient use.

“There are millions of people living with obesity and diabetes who need treatment options, and we know there are therapies still waiting to be discovered that could change their lives,” said Novo CEO Mike Doustdar. “Integrating AI in our everyday work gives us the ability to analyze datasets at a scale that was previously impossible, identify patterns we could not see, and test hypotheses faster than ever.”

That statement goes to the heart of the current transformation in life sciences. Drug discovery has historically been a long, expensive, and failure-prone process, often taking more than a decade and billions of dollars from molecule screening to regulatory approval. AI’s promise lies in reducing attrition rates early in the pipeline by spotting molecular patterns, biomarker relationships, and trial signals that conventional methods may miss.

OpenAI chief executive Sam Altman framed the partnership in broader industry terms.

“AI is reshaping industries and in life sciences, it can help people live better, longer lives,” Altman said. “This collaboration with Novo Nordisk will help them accelerate scientific discovery, run smarter global operations, and redefine the future of patient care.”

However, the scope of the partnership extends well beyond laboratory research. According to the company, OpenAI’s capabilities will also be deployed in manufacturing, supply chain optimization, distribution, and commercial operations, suggesting that Novo is seeking productivity gains across its entire value chain rather than limiting AI to drug screening alone.

In pharmaceuticals, the real bottlenecks often emerge not only in discovery but also in trial design, patient recruitment, site selection, regulatory documentation, and production scaling. These are precisely the areas where AI can generate faster near-term returns.

Industry experts have repeatedly noted that while the idea of AI “discovering the next miracle drug” captures headlines, the more immediate commercial upside often lies in operational acceleration.

Clinical trial optimization, for instance, remains one of the most time-consuming stages of development. AI can help identify patient populations, predict dropout risks, improve site matching, and streamline protocol design, shaving months off timelines and potentially saving hundreds of millions of dollars.

That matters enormously for Novo Nordisk at this moment as the company has been under mounting pressure to defend its position in the obesity market, where its flagship brands Wegovy and Ozempic once gave it a commanding first-mover advantage. That lead has narrowed as Eli Lilly expands aggressively with rival therapies and newer oral formulations.

Novo is now trying to claw back market share through its Wegovy pill and a next-generation pipeline that investors are watching closely. The market’s immediate reaction suggests investors view the OpenAI partnership with interest. Shares rose about 2.8% shortly after the opening bell, with some reports showing gains above 3% in premarket trade.

There is also a longer strategic arc here. This latest deal builds on Novo’s prior AI initiatives, including its collaboration with Nvidia and the use of Denmark’s Gefion sovereign AI supercomputer to accelerate biomedical research. Gefion has already been positioned as a core pillar of Denmark’s AI research infrastructure, and Novo’s latest move suggests the company is layering best-in-class generative AI capabilities on top of that compute backbone.

This points to a larger industry trend where the pharmaceutical race is increasingly becoming a contest of data infrastructure, computing power, and model sophistication.

The partnership thus goes beyond simply discovering drugs faster to restoring competitive momentum, protecting margins, accelerating time-to-market, and ensuring that Novo’s next blockbuster reaches patients before rivals do.

Oracle leads as Tech Shares Rebound, Software Surge Signals Potential Return to Record Highs

0

After a punishing start to 2026 that wiped billions of dollars off technology valuations and briefly pushed the sector back toward pre-ChatGPT pricing levels, Wall Street is beginning to see the outlines of a renewed rally.

Software stocks, led by Oracle’s double-digit jump, saw a sharp rebound on Monday, with the development being interpreted not as a fleeting bounce but as the opening phase of a broader technology recovery.

The rally comes at a moment when investor sentiment toward growth stocks is undergoing a rapid reassessment. For much of the first quarter, technology shares were battered by geopolitical instability, particularly the Iran conflict and the resulting energy-price shock, alongside persistent concerns that the AI boom had left valuations overstretched. That correction, however, has now compressed multiples to levels many strategists consider historically attractive.

At the forefront of Monday’s rebound was Oracle, whose shares surged as much as 12%, making it one of the strongest performers in both software and the broader technology sector. The stock’s advance helped propel the software complex to its best day in roughly a year, reinforcing the view that institutional investors are beginning to rotate back into beaten-down AI and enterprise software names.

The significance of Oracle’s move goes beyond a single-session price spike. The company has become a proxy for investor confidence in enterprise AI infrastructure spending. Its cloud expansion, large contracted revenue backlog, and positioning in database and data-center infrastructure make it a bellwether for whether legacy software companies can successfully monetize AI rather than be displaced by it.

What makes the current setup especially compelling for bulls is the sharp compression in valuations.

“Tech valuations are now LOWER than they were when ChatGPT was announced,” Adam Kobeissi, founder of The Kobeissi Letter, said. “As the Iran War drives markets lower, AI is only getting bigger. Record highs are on the horizon.”

That assessment has found support among other market voices. Apollo chief economist Torsten Slok has similarly noted that sector multiples have fallen from around 40 times earnings to roughly 20 times, effectively erasing much of the premium built during the AI frenzy of 2023 through 2025.

This reset is crucial because, unlike previous speculative bubbles, earnings expectations have not collapsed alongside prices.

According to BlackRock, the technology sector is still projected to deliver approximately 43% earnings growth in 2026, a remarkably strong figure that suggests the selloff was driven more by macro fear and profit-taking than by a deterioration in corporate fundamentals.

That divergence between falling valuations and stable earnings estimates is one reason strategists increasingly describe the current moment as a buy-the-dip opportunity rather than the start of a prolonged bear market.

Daniel Newman, chief executive of Futurum, described the present environment as “a historically opportune moment” to re-enter the AI trade.

The AI story itself remains the central pillar of the bull case. Even as war-driven volatility pressured markets, the underlying capital expenditure cycle tied to artificial intelligence has continued to expand. Hyperscalers and enterprise software companies are still investing massive sums in compute, cybersecurity, data storage, and AI tools. This suggests that the secular demand story remains intact even as share prices undergo cyclical corrections.

Importantly, investors are becoming more selective. Rather than buying technology indiscriminately, capital is increasingly flowing toward companies viewed as essential infrastructure providers or those seen as least vulnerable to AI disintermediation. This includes names such as Microsoft, Alphabet, Meta, Amazon, and NVIDIA, all of which remain deeply embedded in the AI ecosystem through cloud services, chips, platforms, or advertising engines.

Cybersecurity is another area drawing heightened attention. As geopolitical risks intensify and AI tools raise the stakes around enterprise security, firms such as CrowdStrike, Palo Alto Networks, and Zscaler are increasingly being viewed as structural beneficiaries of the next technology upswing.

Another major catalyst now in focus is earnings season. First-quarter corporate results are expected to begin shortly, and analysts broadly expect technology to once again lead profit growth across the S&P 500. This matters because earnings will determine whether the recent rally develops into a sustained re-rating.

Analysts believe that if large-cap tech companies deliver resilient revenue growth and strong AI monetization metrics, investors may gain the confidence needed to push the sector back toward all-time highs.

Goldman Sachs has already pointed to “secular growth” stocks, many of them concentrated in technology, as best positioned for the next expansion phase. That view is reinforced by the market’s gradual shift away from purely macro-driven selling toward stock-specific fundamental analysis.

The broader narrative, therefore, is one of transition – as demonstrated by the first quarter, which was defined by de-risking, war headlines, and multiple compressions. The second quarter is expected to increasingly be defined by earnings validation, AI monetization, and renewed institutional positioning.

Monday’s software rally may prove to be the first meaningful signal that investors believe the valuation reset is complete and that the next leg of the AI-driven tech cycle is beginning. Analysts note that if earnings confirm that thesis, the sector could indeed be laying the groundwork for a fresh run toward record territory.

BP’s Oil Traders Reap Windfall from Iran Conflict as Debt Climbs on Price Surge

0

British Petroleum (BP) delivered a striking early signal of strength on Tuesday, announcing that its oil trading desk posted “exceptional” results in the first quarter of 2026.

The windfall stemmed directly from the sharp surge in crude prices and heightened market volatility triggered by the escalation of conflict in the Middle East since late February. The update, released ahead of full quarterly results scheduled for April 28, echoes a similar upbeat trading message from rival Shell the previous week and underscores how geopolitical shocks continue to reshape fortunes across the energy sector.

The conflict, sparked by U.S. and Israeli actions against Iran, has disrupted supplies through the Strait of Hormuz, a chokepoint carrying roughly one-fifth of global oil and gas flows. Brent crude averaged $81.13 per barrel during the January-to-March period, a meaningful jump from $63.73 in the fourth quarter of 2025.

Prices spiked dramatically in March, at times approaching or exceeding $100–120 per barrel amid attacks on facilities, temporary closures, and retaliatory measures. As of Tuesday, front-month U.S. crude futures hovered near $97, while June Brent contracts traded around $98–99, reflecting persistent tensions even after a fragile two-week ceasefire and stalled peace efforts.

BP’s traders thrived in the chaotic environment. Wide spreads between marker prices and realized values, combined with rapid swings in crude, natural gas, and refined products, created rich opportunities for arbitrage, inventory management, and optimization. The company explicitly contrasted this performance with a “weak” fourth-quarter outcome, noting that the latter part of Q1 saw particularly intense dislocation. While full segment breakdowns await the April 28 release, the trading uplift is expected to provide a significant offset to any upstream or downstream pressures.

Shell similarly flagged meaningfully stronger trading and optimization results in its own early Q1 preview, highlighting how volatility benefits well-positioned desks even when physical operations face headwinds such as reduced Qatari LNG volumes.

Debt Rises on Working Capital Demands

The good news on trading, however, came with a caveat. BP expects net debt at the end of March to land between $25 billion and $27 billion, up from $22.2 billion at year-end 2025. The primary driver is a substantial working-capital build, estimated at $4—7 billion, necessitated by the higher price environment. Elevated crude values inflate the cost of inventories and receivables, tying up cash even as margins improve elsewhere. Organic capital expenditure is projected to remain broadly flat at around $3.5 billion, with upstream production broadly steady quarter-on-quarter.

Investors have grown accustomed to such swings. In periods of rapid price escalation, majors routinely see balance-sheet expansion before cash flows normalize. BP’s management has long emphasized financial resilience, yet the increase serves as a reminder that commodity supercycles demand careful liquidity stewardship. Shareholders may temper hopes for aggressive buybacks or special dividends until the working-capital cycle unwinds.

Markets are closely watching diplomatic maneuvers as they are expected to shape future trades. President Donald Trump stated Monday that Iran “would like to make a deal very badly,” while Vice President JD Vance emphasized that next steps rest with Tehran following inconclusive weekend talks.

Reuters reported potential resumption of discussions in Islamabad as soon as this week. On the operational front, the U.S. implemented a blockade of Iranian ports and the Strait of Hormuz beginning Monday, aiming to squeeze Tehran’s oil revenue while keeping lanes open for non-Iranian traffic. Trump described the dual objective as forcing both reopening of the strait and broader negotiations—“both of those things, certainly, and more.”

Any swift resolution would ease supply fears, but analysts caution that prolonged disruption could cascade through global markets. HSBC Holdings Chair Brendan Nelson, speaking at the HSBC Global Investment Summit in Hong Kong, stressed that a Middle East peace deal is “essential” to restore substantial energy flows.

But as long as uncertainty lingers, energy prices will stay elevated, feeding into broader inflation risks and tighter financial conditions. Nelson urged caution on current growth, trade, and inflation forecasts, noting that indirect effects from higher energy costs, felt across transport, manufacturing, and consumer prices, will intensify the longer the situation persists.

“The longer the disruption continues, the more the indirect effects from higher energy costs will lift inflation and depress growth,” Nelson said.

He anticipates interest rates remaining on hold across the U.S., Europe, and Britain this year amid already elevated market rates.

However, the current environment presents a classic trade-off for BP and its peers: near-term trading and refining margin gains against longer-term risks of demand destruction, higher operating costs, and potential recessionary pressure if energy inflation bites too deeply.

BP’s production mix, particularly lagged pricing in the Gulf of America and UAE, means some realization benefits will flow through with delay, while gas marketing and trading is expected to deliver only an average performance.

Ondo Finance Submitted a No-action Letter Request to the U.S. SEC 

0

Ondo Finance submitted a no-action letter request to the U.S. Securities and Exchange Commission (SEC). The filing seeks SEC staff assurance that it would not recommend enforcement action if Ondo uses Ethereum Mainnet to record and administer certain securities entitlements in tokenized form, while keeping the official legal books, records, custody, and underlying ownership unchanged.

What Ondo wants to do: For its OGM product; tokenized notes giving non-U.S. investors exposure to over 200 U.S.-listed stocks and ETFs, Ondo proposes representing securities entitlements; interests in the underlying assets as tokens on Ethereum. The actual underlying securities would continue to be held and custodied traditionally via BitGo and a U.S. broker-dealer like Alpaca, with records potentially tied to systems like DTC.

Ethereum would serve mainly as an operational layer for recordkeeping, collateral management, and faster synchronization—not as a replacement for legal ownership or the primary ledger. This is narrowly tailored to OGM and does not seek broad changes to securities laws, new broker-dealer registration requirements, or permission for fully on-chain securities settlement.

It frames blockchain as an efficiency tool that coexists with existing regulated infrastructure. Ondo argues the model maintains full compliance with custody, disclosure, and recordkeeping rules. It could enable benefits like near-instant settlement, 24/7 operations, and improved collateral handling without introducing new regulatory risks. This comes shortly after the SEC closed a two-year investigation into Ondo without charges.

Ondo has previously submitted comments to the SEC advocating for tokenized securities frameworks, including support for public blockchains in RWA markets. A favorable no-action letter (if granted) would not be binding law or a formal rule, but it would provide regulatory comfort and a precedent that public, permissionless blockchains like Ethereum can integrate into U.S. securities recordkeeping without triggering enforcement.

It is often described as potentially the first formal regulatory confirmationn of this kind for tokenized equities exposure. The broader tokenized real-world assets (RWA) sector currently around $20–25B in TVL, with Ondo holding a significant share could benefit. Success here might encourage other issuers to pursue similar compliant hybrid models combining TradFi custody with blockchain efficiency.

It aligns with growing institutional interest in RWAs, where tokenization aims to improve liquidity, accessibility, and settlement speed while respecting existing regulations. No-action letters can be modified or withdrawn, and the SEC has not yet responded publicly. The request is available via Ondo’s blog and SEC-related submissions.

This is a notable step in bridging traditional securities infrastructure with blockchain for RWAs, particularly for non-U.S. investor access to U.S. equities and ETFs. Developments will likely depend on the SEC’s stance under current leadership.

If granted, this would provide the first formal SEC staff comfort that a permissionless blockchain can be integrated into U.S. securities recordkeeping as an operational layer, without replacing legal ownership, custody, or official books. It signals a hybrid model (TradFi custody + blockchain efficiency) is viable, reducing uncertainty for similar tokenized setups.

Enables faster near-instant settlement, 24/7 operations, improved collateral monitoring, and streamlined subscription and redemption processes for non-U.S. investors gaining exposure to 200+ U.S. stocks and ETFs. The underlying assets remain held traditionally via BitGo and broker-dealers, keeping full regulatory compliance intact.

Boosts confidence in tokenized real-world assets. It could accelerate institutional adoption by demonstrating compliant ways to use public chains for efficiency gains, potentially unlocking more capital flows into RWAs without overhauling securities laws. The tokenized securities market is projected to see significant growth in coming years.

Viewed as a flow catalyst post-SEC investigation closure. It has generated positive buzz in crypto communities, highlighting Ondo’s leadership in institutional tokenization and potential for broader RWA expansion. Short-term price reaction has been modest (ONDO up ~2-3% in initial reports), but longer-term implications could support growth if approved.

Goldman Sachs Actively Using Anthropic’s Claude Mythos to Strengthen its Cybersecurity Posture 

0

Goldman Sachs is actively using and collaborating on Anthropic’s Claude Mythos Preview often shortened to Mythos to strengthen its cybersecurity posture.

Anthropic released Claude Mythos Preview in early April 2026 as part of its “Project Glasswing” initiative focused on cybersecurity. It’s a frontier-level AI model that shows major leaps in agentic capabilities—particularly in autonomous vulnerability discovery, exploit chaining, and security research. Anthropic has described it as capable of finding and exploiting software vulnerabilities at a level rivaling or surpassing top human researchers, including in complex, real-world systems.

The company has restricted public access due to the dual-use risks: the same tech that excels at defense could dramatically lower the bar for sophisticated cyberattacks if misused. Access is limited to select trusted partners, with some involvement from U.S. government encouragement. Goldman Sachs CEO David Solomon publicly stated that the bank is hyper-aware of Mythos’s capabilities.

The firm has access to the model. Is working closely with Anthropic and its security vendors. Is supplementing and accelerating investments in cyber and infrastructure resilience to harness frontier AI tools for defense. This follows an urgent meeting last week convened by U.S. Treasury Secretary Scott Bessent and Federal Reserve Chair Jerome Powell with major bank CEOs.

Officials warned about the heightened cyber risks from advanced AI models like Mythos and reportedly encouraged banks including Goldman, JPMorgan, Citi, etc. to test it internally on their own systems to identify and patch weaknesses proactively. In short, Goldman is flipping the script: instead of just fearing what Mythos could do to them, they’re using it for them—to hunt for hidden vulnerabilities before attackers do.

This fits a growing pattern where frontier AI’s cyber capabilities are forcing a reckoning. Models like Mythos can autonomously scan for flaws, chain exploits, and operate with less human oversight, which is powerful for defenders but alarming for the attack surface of critical infrastructure like banks. U.S. regulators appear to be pushing a test it yourself to defend it approach rather than blanket restrictions.

Other large banks are reportedly in similar testing phases, though Goldman’s public comments from Solomon make it one of the more visible examples so far.The situation highlights the classic AI dual-use dilemma: rapid capability gains in offensive and defensive cyber tools, controlled release by labs like Anthropic, and institutions racing to adapt. It’s less AI is coming for the banks and more the banks are racing to weaponize AI for defense before the bad actors do.

JPMorgan Chase stands out as the only bank explicitly named by Anthropic as a Project Glasswing participant. The bank is actively evaluating Mythos for defensive cybersecurity across critical infrastructure. JPMorgan has described it as a unique, early-stage opportunity to test next-generation AI tools.

The firm already invests heavily in AI overall; part of its $19.2 billion tech budget includes $1.2 billion for AI initiatives and uses advanced techniques like graph neural networks for fraud detection. It reported identifying $150 million in previously undetectable fraud ring activity through such systems.

Citi is among the banks reported to be internally testing Mythos or preparing to gain access. Its CEO Jane Fraser attended the recent Treasury/Fed meeting. Citi has long emphasized AI for operational efficiency like speeding account openings and legacy system upgrades and is ramping up AI-related capex forecasts. It also highlights quantum cybersecurity threats and broader AI-driven fraud/AML integration.

Bank of America is testing Mythos internally, with CEO Brian Moynihan present at the regulators’ meeting. The bank allocates about $4 billion of its $13 billion tech budget to strategic growth areas that include AI. It deploys AI for fraud detection, dispute resolution; handling 62% of card disputes without human intervention in some cases, and broader risk functions.

Morgan Stanley is also internally testing or preparing to test the model, per reports on the Wall Street banks involved. Its CEO Ted Pick attended the meeting. Like peers, it integrates AI into compliance, risk, and operational workflows, though specific Mythos details remain limited due to the controlled nature of access.

Wells Fargo’s CEO Charlie Scharf attended the urgent meeting. While public details on its direct Mythos testing are scarcer than for JPMorgan or Goldman, it is part of the group of major banks urged by regulators to evaluate the tool for vulnerability hunting. The bank continues to prioritize AI in fraud detection, cybersecurity oversight, and technology modernization